These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 39020302)
1. LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation. Chen Y; Wu S; Han Y; Shi H; Yuan J; Cui W BMC Cancer; 2024 Jul; 24(1):848. PubMed ID: 39020302 [TBL] [Abstract][Full Text] [Related]
2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146 [TBL] [Abstract][Full Text] [Related]
3. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Cai Y; Dong ZY; Wang JY Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323 [TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis. Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110 [TBL] [Abstract][Full Text] [Related]
5. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer. Shen Q; Xu Z; Xu S Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379 [TBL] [Abstract][Full Text] [Related]
6. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Fu J; Cai H; Wu Y; Fang S; Wang D Gene; 2020 Sep; 755():144886. PubMed ID: 32534055 [TBL] [Abstract][Full Text] [Related]
7. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis. Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246 [TBL] [Abstract][Full Text] [Related]
8. Soy isoflavone genistein inhibits hsa_circ_0031250/miR-873-5p/FOXM1 axis to suppress non-small-cell lung cancer progression. Yu Y; Xing Y; Zhang Q; Zhang Q; Huang S; Li X; Gao C IUBMB Life; 2021 Jan; 73(1):92-107. PubMed ID: 33159503 [TBL] [Abstract][Full Text] [Related]
9. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
10. LncRNA NNT-AS1 promotes lung squamous cell carcinoma progression by regulating the miR-22/FOXM1 axis. Ma J; Qi G; Li L Cell Mol Biol Lett; 2020; 25():34. PubMed ID: 32514270 [TBL] [Abstract][Full Text] [Related]
11. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020 [TBL] [Abstract][Full Text] [Related]
12. LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis. Yu Z; Wang G; Zhang C; Liu Y; Chen W; Wang H; Liu H Cell Cycle; 2020 Feb; 19(3):300-316. PubMed ID: 31928130 [No Abstract] [Full Text] [Related]
13. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053 [TBL] [Abstract][Full Text] [Related]
14. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis. Huang Q; Xing S; Peng A; Yu Z Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841 [TBL] [Abstract][Full Text] [Related]
15. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072 [TBL] [Abstract][Full Text] [Related]
16. Knockdown of circLRWD1 weakens DDP resistance via reduction of SIRT5 expression through releasing miR-507 in non-small cell lung cancer. Deng Z; Tu Q; Hu G; Xing M Anticancer Drugs; 2022 Oct; 33(9):861-870. PubMed ID: 35946561 [TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA LINC00339 facilitates the tumorigenesis of non-small cell lung cancer by sponging miR-145 through targeting FOXM1. Yuan Y; Haiying G; Zhuo L; Ying L; Xin H Biomed Pharmacother; 2018 Sep; 105():707-713. PubMed ID: 29906749 [TBL] [Abstract][Full Text] [Related]
18. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Wang L; Shang X; Feng Q Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109 [TBL] [Abstract][Full Text] [Related]
19. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2. Wang W; Dong ML; Zhang W; Liu T Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373 [TBL] [Abstract][Full Text] [Related]
20. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP. Tan D; Wang S; Zhang P; Peng C; Wu T Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]